FDA Commissioner to Meet with Indian Regulatory Authorities - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

FDA Commissioner to Meet with Indian Regulatory Authorities


FDA has announced that Commissioner Margaret A. Hamburg, MD will make her first official trip to India on Feb. 10-18 to further strengthen cooperation between the FDA and its Indian regulatory counterparts.

During the trip, which will include visits to Delhi, Cochin, and Mumbai, Hamburg will meet with Indian policy and government leaders involved in the regulation of medical and food products exported to the United States.  Currently, India is the second largest provider of finished drug products and the eighth largest exporter of food products to the United States. 

“The FDA’s ongoing engagement with our regulatory counterparts in India is critical to our ability to effectively promote the health and safety of American and Indian consumers,” said Commissioner Hamburg. “I look forward to enhancing our existing relationship and identifying additional opportunities for collaboration.”

The US and Indian food and drug officials share information on the conduct of clinical trials and address product safety issues that may have an impact on both American and Indian consumers. Commissioner Hamburg will also meet with industry leaders in India to discuss the importance of maintaining high-quality standards in producing goods to ensure consumers have access to safe products, FDA reports.

Source: FDA

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes

Click here